ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs MXN
18.4136
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,465.93
0.19%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Virpax Pharmaceuticals Inc (VRPX)

  7. Virpax Pharmaceuticals Inc (VRPX) Noticias

VRPX Virpax Pharmaceuticals Inc

0.72
-0.0805 (-10.06%)
07 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Virpax Pharmaceuticals Inc VRPX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.0805 -10.06% 0.72 16:56:48
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.81 0.74 0.813038 0.7501 0.8005
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/5/202406:30BWVirpax® Pharmaceuticals to Present at 2024 BIO International..
17/5/202415:05EDGAR2Form 8-K - Current report
16/5/202415:00EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
15/5/202407:00BWVirpax Announces Pricing of $2.25 Million Public Offering
14/5/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
13/5/202416:30EDGAR2Form S-1/A - General form for registration of securities..
13/5/202415:20EDGAR2Form 8-K - Current report
13/5/202415:10BWVirpax Pharmaceuticals Reports 2024 First Quarter Results..
13/5/202415:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30/4/202406:30BWVirpax Announces Results of Maximum Tolerated Dose Study for..
26/3/202406:30BWVirpax Pharmaceuticals Reports 2023 Year-End Results
27/2/202406:31BWVirpax Pharmaceuticals Announces Reverse Stock Split to..
27/2/202406:30BWVirpax Pharmaceuticals Announces Proposed Settlement of..
07/2/202406:30BWVirpax Pharmaceuticals Announces Preliminary Results of..
31/1/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202415:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202415:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202415:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202415:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202306:30EDGAR2Form 8-K - Current report
29/12/202306:30BWVirpax Pharmaceuticals Announces Results of Special..
13/12/202307:30EDGAR2Form 8-K - Current report
07/12/202308:08EDGAR2Form DEF 14A - Other definitive proxy statements
07/12/202307:58EDGAR2Form 8-K - Current report
07/12/202307:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21/11/202315:57EDGAR2Form PRE 14A - Other preliminary proxy statements
17/11/202306:30EDGAR2Form 8-K - Current report
17/11/202306:15EDGAR2Form 8-K - Current report
17/11/202306:10BWVirpax Pharmaceuticals Announces Notification from Nasdaq..
17/11/202306:00BW Virpax Pharmaceuticals Announces Leadership Transition
16/11/202315:51EDGAR2Form 8-K - Current report
15/11/202315:15BWVirpax Pharmaceuticals Reports 2023 Third Quarter Results..
15/11/202314:03EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
31/10/202307:58BWVirpax Pharmaceuticals Announces that Envelta™ Remains on..
12/10/202307:02BWVirpax Pharmaceuticals Announces Extension of CRADA with the..
11/10/202315:10EDGAR2Form 8-K - Current report
03/10/202308:51EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/10/202307:58BWGerald W. Bruce Appointed President and CEO of Novvae™..
27/9/202307:58BWVirpax Pharmaceuticals Announces Results of Probudur™ Dose..
26/9/202307:58BWVirpax Pharmaceuticals to Present at the LD Micro Main Event..
21/9/202312:35BWAltasciences von Virpax ausgewählt, um die Entwicklung eines..
21/9/202312:18BWAltasciences choisi par Virpax pour soutenir le..
21/9/202309:00BWAltasciences Chosen by Virpax to Support the Development of..
18/9/202306:58BWVirpax Pharmaceuticals Announces the Formation of Novvae™..
05/9/202308:28EDGAR2Form 8-K - Current report
05/9/202308:00BWVirpax Pharmaceuticals Updates on Litigation
28/8/202307:58BWVirpax® Pharmaceuticals to Present at H.C. Wainwright 25th..

Su Consulta Reciente

NASDAQ
VRPX
Virpax Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados